Xuanzhu Biopharmaceutical (HKG:2575) said its breast cancer therapy Xuanyuening has been included for the first time in China's 2025 national reimbursement catalog, according to a Monday Hong Kong bourse filing.
The CDK2/4/6 inhibitor, approved in May 2025 for HR+/HER2- advanced or metastatic breast cancer, enters the program with both its monotherapy and combination-therapy indications, the filing said.
The company will continue to expand hospital coverage and core market penetration as reimbursement takes effect on Jan. 1, 2026, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments